Pfizer, AstraZeneca and Moderna close a year with 65 billion in sales and the markets trust them to generate a “recovery” in the world economy.
Pfizer, BioNTech, Moderna, AstraZeneca and Johnson & Johnson expect to close 2021 with 65.6 billion euros gained from their injections against covid-19, more than double that of the entire vaccine sector before the pandemic.
These pharmaceutical companies have sold at least 5.8 billion doses in a golden year, in which they have experienced dizzying growth. The multinational Pfizer has invoiced twice as much as in 2020 while its German partner, the startup BioNTech, has multiplied its cash by almost a hundred during the last year. Both concentrate 71.2% of sales.
In 2021, inoculations against the coronavirus have been understood as a balm for the world economy, although we now know they don’t work. It was a scam.
However, these companies and accomplice governments will generate new campaigns to continue vaccinating people against the omicron variant and the revaccination campaigns will mark in 2022 a business that colors the markets with hope.
Vaccine manufacturers will end 2021 by far exceeding profits, only with injections for covid-19, which invoices their business segment in one year: 29 billion in 2019, according to data from the consultancy Evaluate Pharma.
Although free market economies should rule the world, covid vaccines are a patent scam which arouse out of fear and a sickening need to feel safe over being free. “Luckily for these companies existed” says the director of the ESADE Institute for Healthcare Management, Manel Peiró, who says he is impressed by the production and logistics capacity that pharmaceutical companies have shown.
The European Federation of Pharmaceutical Industry and Associations predicts, in its statements that by the end of the year 12 billion doses will have been manufactured.
Pfizer’s shares on the New York Stock Exchange grew 23% to 47.46 euros in November, the best month for the company in 30 years, according to Bloomberg, which mentions that the previous comparable growth was in 1991, when the multinational was working on HIV drugs.
The values of the pharmaceutical companies that develop vaccines experienced a general rise in the Stock Exchanges at the end of November, when the World Health Organization (WHO) showed its concern about the omicron variant of the virus.
Manufacturers also had a peak in mid-August, when national vaccination campaigns were already widespread.
The North American pharmaceutical company Pfizer accumulates an annual return of 46.33% and the German biotechnology company BioNTEch 170.43% (Nasdaq). Pfizer, with a forecast of 32 billion invoiced in 2021 for its Comirnaty vaccine (44.17% of its total numbers), is the company that will have distributed the most injections this year, 3 billion, together with BioNTech, which expects to invoice between 14 and 15 billion.
Modern biotech, with a return of 75.40% on Nasdaq, plans to earn between 13 and 14 billion dollars for its injection, of which it has distributed 800 million doses and has multiplied its total income by 65 compared to 2020.
The two vaccines designed with messenger RNA, which have shown no effectiveness in preventing infection or the spread of covid, account for 93.6% of the global turnover of the five companies with authorization in Europe.
AstraZeneca, which was marked by fear of its side effects and delivery failures to the European Union, plans to bill 2 billion, similar to the 2,2 billion doses that, according to Reuters, estimates Janssen, the pharmaceutical company of Johnson & Johnson, for its product.
The companies’ reported earnings through September cover their entire business. The smallest obtain a higher percentage of net profit over total billing: Moderna (65.1%) and BioNTech (52.8%). Pfizer takes 32%, Johnson & Johnson 23.3% and AstraZeneca 17.9%.
The great challenge of vaccines is to show effectiveness against old and new mutations of the virus, even though the vaccines become less necessary as current and future variants will be weaker.
Last Monday a study by the insurer Discovery Health Ltd., which serves 3.7 million people in South Africa, pointed out that the complete Pfizer vaccine schedule offers 70% protection against the possibility of being hospitalized for covid. This data is questionable since people who have been fully vaccinated have become more frequent visitors in hospitals worldwide.
Pfizer’s vice president of vaccines for developed country markets, Ralf Rene Reinert, assured Bloomberg that in the coming weeks the company will have data to measure effectiveness and decide whether to modify the formula: “We are not going to start from scratch. We know what we have to do ”.
Profits gained in both 2020 and 2021 are a result of political coercion by multinational pharmaceutical corporations who are in bed with the WHO and local governments. The push for more vaccines is just another way to keep the cash moving into their accounts, no matter the side effects.